SNP-apyrase for oral use in the treatment of IBD
• Lead compound, MV010, has shown animal PoC in a murine model of ulcerative colitis.
• Abrogation of the pro-inflammatory function of extracellular ATP in the intestine without systemic immune suppression.
• Amplification of secretory IgA production in Peyer's patches and gut-associated lymphoid tissue (GALT), ensuring high specificity for individual immune regulation.
• Promotion of a healthy microbiome by enhancing the binding of secretory IgA to bacterial antigens, thereby reducing dysbiosis—a key factor in IBD.
• Absence of systemic side effects compared to standard of care by limiting the pharmacological action of apyrase to the gut and implementing the gut-specific function of IgA
• Easy extension to other dysbiotic conditions such as Crohn’s Disease, Dysbiosis and others.
